NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: LP Peptide

Published 12 Nov 2026. 34-page investigative report on who is behind LP Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

LP Peptide is not a simple pass/fail vendor. Across 98 Finnrick lab tests, the supplied record shows 51 pass and 46 fail — an overall pass rate of 52%. The signal is product-specific: GHK-Cu is the strongest relative line, Retatrutide carries the largest absolute failure burden, and Tesamorelin plus NAD+ sit in the clearest caution zone. Under stricter grading, ratings compress further, making exact-lot verification the buyer decision point.

The business record is thinner than the storefront. The domain dates to March 2026, the site was redesigned into a warehouse-model shop by October, and reviewed public pages do not identify a legal seller, beneficial owner, merchant of record, governing law or quality decision-maker. That is a transparency limit, not proof competent personnel do not exist; it means responsibility is not publicly attributable before payment.

The investigation maps a wider storefront ecosystem. A Yuan Peptide catalog PDF sits behind much of the product API and tracks LP prices closely, while adjacent storefronts reuse LP-style product handles, supply copy and theme assets. LP Peptide’s 24 COAs are better than a badge, but they do not name the lab or accreditation and cannot be matched publicly to the vial lot that would ship.

Operationally, LP Peptide pairs regional warehouse claims with crypto-only checkout, a $199 minimum, a 5% handling fee and no published refund counterparty. The full report also documents an affiliate program without a promoter-disclosure clause, review counts that do not reconcile, and lookalike domains that make channel authentication a practical issue.

Inside the full report:

  • Finnrick product trajectories and methodology-divergence charts for all 9 tested products
  • RDAP, archive and policy-page exhibits tracing domain age, redesign and attribution gaps
  • Yuan catalog and shared-build analysis across LP Peptide, AGO Research, TSLpeptide and clones
  • 24-certificate COA register with missing lab, accreditation, method and lot-match flags
  • Checkout, warehouse, affiliate, review-metric and recourse exhibits

Risk assessment

  • Tesamorelin quality concern — high: Tesamorelin: 14 tests, 5 pass / 9 fail, 41.4%; avoid without a fresh independent exact-lot pass.
  • NAD+ quality concern — high: NAD+: 4 tests, 0 pass / 4 fail, 18.59%; no positive independent signal.
  • MOTS-c quality concern — high: MOTS-c: 3 tests, 0 pass / 3 fail, 28.87%; no positive independent signal.
  • Legal-counterparty and ownership opacity — high: No owner, entity, merchant, address, governing law or refund counterparty is disclosed on the reviewed public record.
  • COA and lot-traceability concern — high: 24 COAs lack lab identity/accreditation and do not link public certificates to the lot that would ship.
  • Payment and recourse concern — high: $199 minimum, 5% handling fee, crypto-only checkout and no published refund, payee or return process.
  • CJC-1295 quality concern — medium: CJC-1295: 2 tests, 0 pass / 2 fail, 25.83%; small sample but entirely negative.
  • Retatrutide quality concern — medium: Retatrutide: 39 tests, 24 pass / 15 fail, 63.91%; largest absolute failure count in LP Peptide's record.
  • Tirzepatide quality concern — medium: Tirzepatide: 14 tests, 8 pass / 6 fail, 65.63%; mixed record requiring exact-lot verification.
  • BPC-157 quality concern — medium: BPC-157: 6 tests, 3 pass / 3 fail, 50.67%; split record with no margin for trust-by-brand.
  • GHK-Cu lot-verification concern — medium: GHK-Cu is LP Peptide's strongest tested product, but 13 tests still include 4 failures; verify the exact lot.
  • Brand-authentication and lookalike-domain concern — medium: lppeptide-au.com clone, lp-peptide.com lookalike and no official authorized-channel list for buyers to rely on.
  • Sourcing-accountability and factory-direct claim concern — medium: Yuan catalog links and identical AGO/TSL storefronts conflict with LP Peptide's no-reseller factory-direct claim.
  • Affiliate-promotion disclosure concern — medium: 10% affiliate program lacks a disclosure clause, and one X referral-code placement had no clear disclosure.
  • Review-metric integrity concern — medium: RT10 shows 5,725 verified buyers while its star breakdown sums to 1,066; API review, sales and stock metrics are unreconciled.